Favourable Results of Patritumab Deruxtecan in Patients with Leptomeningeal Metastatic Disease of Solid Tumours By Ogkologos - July 21, 2025 222 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TUXEDO-3 study Source RELATED ARTICLESMORE FROM AUTHOR European Parliament Adopts Its Position on the Critical Medicines Act, Strengthening Security of Cancer Care in Europe ESMO Raises Key Issues on Cancer Prevention and Care at the WHO Executive Board Meeting Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer MOST POPULAR Breast Cancer May Spread by Recruiting Nearby Sensory Nerves September 20, 2024 “Giving something back”: our supporters are the beating heart of what... August 17, 2022 Targeted Radiation Reduces Pain from Cancer Metastases in the Spine November 24, 2020 Adding Blinatumomab to Consolidation Chemotherapy Improves OS in Adult Patients in... August 12, 2024 Load more HOT NEWS EMA Recommends Extension of Indications for Atezolizumab Five Questions with…Debra. Temporary Interruption of Adjuvant Endocrine Treatment to Attempt Pregnancy Does Not... A new approach to cancer immunotherapy
